Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Upstream Bio (UPB) Research & Development (2023 - 2025)

Upstream Bio has reported Research & Development over the past 3 years, most recently at $40.2 million for Q4 2025.

  • Quarterly results put Research & Development at $40.2 million for Q4 2025, up 84.49% from a year ago — trailing twelve months through Dec 2025 was $136.8 million (up 117.27% YoY), and the annual figure for FY2025 was $136.8 million, up 117.27%.
  • Research & Development for Q4 2025 was $40.2 million at Upstream Bio, up from $33.0 million in the prior quarter.
  • Over the last five years, Research & Development for UPB hit a ceiling of $40.2 million in Q4 2025 and a floor of $7.8 million in Q3 2023.
  • Median Research & Development over the past 3 years was $18.6 million (2024), compared with a mean of $21.9 million.
  • Peak annual rise in Research & Development hit 169.14% in 2025, while the deepest fall reached 84.49% in 2025.
  • Upstream Bio's Research & Development stood at $11.6 million in 2023, then soared by 88.45% to $21.8 million in 2024, then skyrocketed by 84.49% to $40.2 million in 2025.
  • The last three reported values for Research & Development were $40.2 million (Q4 2025), $33.0 million (Q3 2025), and $37.9 million (Q2 2025) per Business Quant data.